within Pharmacolibrary.Drugs.ATC.D;

model D05AX04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05AX04</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tacalcitol is a synthetic vitamin D3 analogue used mainly as a topical treatment for mild to moderate plaque psoriasis. It exerts its effects by modulating the growth and differentiation of keratinocytes. Tacalcitol is not widely approved in all countries and is primarily available in select regions for dermatological use.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic parameters (such as volume of distribution, clearance, or absorption rate constants) have been reported in the literature for tacalcitol in humans. Available data suggest minimal systemic absorption from topical application and a pharmacokinetic profile similar to other vitamin D analogues.</p><h4>References</h4><ol><li><p>Peters, DC, &amp; Balfour, JA (1997). Tacalcitol. <i>Drugs</i> 54(2) 265–272. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199754020-00005&quot;>10.2165/00003495-199754020-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9257082/&quot;>https://pubmed.ncbi.nlm.nih.gov/9257082</a></p></li><li><p>Mortensen, JT, et al., &amp; Binderup, L (1996). Toxicity of 1,25-dihydroxyvitamin D3, tacalcitol, and calcipotriol after topical treatment in rats. <i>The journal of investigative dermatology. Symposium proceedings</i> 1(1) 60–63. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9627694/&quot;>https://pubmed.ncbi.nlm.nih.gov/9627694</a></p></li><li><p>Ohta, T, et al., &amp; Kiyoki, M (1996). In vivo microautoradiography of [3H]1,24(OH)2D3 (tacalcitol) following topical application to normal rats and in vitro metabolism in human keratinocytes. <i>Archives of dermatological research</i> 288(4) 188–196. DOI:<a href=&quot;https://doi.org/10.1007/BF02505223&quot;>10.1007/BF02505223</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8967791/&quot;>https://pubmed.ncbi.nlm.nih.gov/8967791</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05AX04;
